AADAC Rabbit Polyclonal Antibody

CAT#: TA323312

Anti-AADAC Rabbit Polyclonal Antibody

Product Images

Gel: 10%SDS-PAGE Lysate: 40 μg Lane 1-2: Human fetal liver tissue Human liver cancer tissue Primary antibody: TA323312 (AADAC Antibody) at dilution 1/550 Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution Exposure time: 1 minute

• 

  Immunohistochemistry of paraffin-embedded Human colon cancer tissue using TA323312 (AADAC Antibody) at dilution 1/30 (Original magnification: ×200)

• 

  Immunohistochemistry of paraffin-embedded Human colon cancer tissue using TA323312 (AADAC Antibody) at dilution 1/30, treated with fusion protein. (Original magnification: ×200)

• 

  Immunohistochemistry of paraffin-embedded Human liver cancer tissue using TA323312 (AADAC Antibody) at dilution 1/30 (Original magnification: ×200)

• 

  Immunohistochemistry of paraffin-embedded Human liver cancer tissue using TA323312 (AADAC Antibody) at dilution 1/30, treated with fusion protein. (Original magnification: ×200)

Show all 5 images

Specifications

Product Data

• Applications: IHC, WB
• Recommended Dilution: WB: 500-2000
  WB positive control: Human fetal liver and liver cancer tissue
  IHC: 25-100
  Positive control: Human colon cancer
  Predicted cell location: Cytoplasm
• Reactivities: Human
• Host: Rabbit
• Isotype: IgG
• Clonality: Polyclonal
• Immunogen: Fusion protein corresponding to C terminal 250 amino acids of human arylacetamide deacetylase
• Formulation: PBS pH7.3, 0.05% NaN3, 50% glycerol
• Concentration: lot specific
• Purification: Antigen affinity purification
• Conjugation: Unconjugated
• Storage: Store at -20°C as received.
• Stability: Stable for 12 months from date of receipt.
• Predicted Protein Size: 46 kDa
• Gene Name: arylacetamide deacetylase
• Database Link:
  NP_001077
  Entrez Gene 13 Human
  UniProt ID P22760
• Background: Microsomal arylacetamide deacetylase competes against the activity of cytosolic arylamine N-acetyltransferase; which catalyzes one of the initial biotransformation pathways for arylamine and heterocyclic amine carcinogens. Arylacetamide deacetylation is an important enzyme activity in the metabolic activation of arylamine substrates to ultimate carcinogens. Displays major serine hydrolase activity in liver microsomes. Hydrolyzes also flutamide; which is an antiandrogen drug used for the treatment of prostate cancer that occasionally causes severe hepatotoxicity. Displays cellular triglyceride lipase activity in liver. Increases intracellular fatty acids derived from hydrolysis of newly formed triglyceride stores.
• Synonyms: CES5A1; DAC

Reference Data

• Protein Families: Druggable Genome, Transmembrane